KISSPEPTIN10.XYZ is a plain-language reference on one ten-residue signalling peptide. Nothing is sold on this site.
Kisspeptin-10
.XYZ
Research

Kisspeptin-10 in research

Context first: The human studies below were small physiological experiments run in specialist research units. They measured hormone responses; they were not trials of a treatment and do not show that kisspeptin-10 is useful or safe as a medicine.

Kisspeptin research spans thousands of papers, but kisspeptin-10 holds a particular place in it. Because it acts directly on GnRH neurons, an injection works almost like pressing a test button on the reproductive axis: if the pituitary hormone luteinising hormone (LH) rises soon afterwards, the chain from the hypothalamus to the pituitary is working. Much of the literature uses it in exactly that way.

Animal and cell studies

  • Direct action on GnRH release (PNAS, 2005): kisspeptin had no effect on gonadotropins in mice lacking GPR54, and when given into the brain of sheep it released GnRH into the cerebrospinal fluid.
  • Primate puberty (PNAS, 2005): in juvenile male monkeys kisspeptin-10 provoked a GnRH discharge, blocked by a GnRH receptor antagonist, and hypothalamic KiSS-1 expression increased at puberty.
  • Desensitisation (Endocrinology, 2006): a continuous infusion of metastin 45–54, which is kisspeptin-10, produced an LH response that collapsed after about three hours, while the pituitary still responded to GnRH. The receptor itself had stopped responding.
  • Short versus long (PLoS One, 2017): in mice kisspeptin-54 kept LH raised far longer than kisspeptin-10, partly because of half-life and possibly because the shorter peptide reaches GnRH neurons behind the blood-brain barrier less well.

Studies in healthy volunteers

  • First dose-response data in men (Edinburgh, 2011): intravenous kisspeptin-10 caused a rapid rise in LH. The highest bolus tested gave a smaller response than the one below it, and a prolonged infusion increased the frequency of LH pulses.
  • Resetting the GnRH clock (Boston, 2011): in 13 men a single injection of the 112–121 decapeptide triggered an immediate LH pulse and delayed the next natural pulse by about one normal interval, as if the hypothalamic pulse generator had been reset.
  • Differences between the sexes (London, 2011): men responded clearly, whereas women in the follicular phase of the cycle showed no gonadotropin change; women near ovulation did respond.
  • Across the menstrual cycle (Boston, 2012): LH pulses followed kisspeptin in all women tested in the luteal and preovulatory phases but in only about half of those in the early follicular phase, and no reset of the pulse generator was seen in women.
  • KP-10, KP-54 and GnRH side by side (London, 2015): with five men per group, the two kisspeptins gave similar LH and FSH responses, and GnRH was roughly two to three times more effective.
  • Repeated exposure (London, 2026): over five days of continuous subcutaneous kisspeptin-10, LH and FSH fell back to the levels seen with placebo, whereas 8-hour daily infusions kept them raised for 12 days, consistent with the receptor staying responsive when it is given breaks.

A test of the reproductive axis in young people

Delayed puberty is common and usually resolves on its own, but a small minority of adolescents have a permanent hormone deficiency, and the two are hard to tell apart early on. In a Boston cohort of 16 children, every child whose LH rose clearly after a kisspeptin stimulation test later progressed through puberty, while every child with a minimal response reached 18 without signs of puberty. A 2026 review discusses kisspeptin as a possible direct test of hypothalamic reproductive function, a role that still has to be confirmed in larger studies.

Beyond the reproductive axis

  • Blood vessels (Endocrinology, 2007): KP-10, KP-13 and KP-54 contracted isolated human coronary artery and umbilical vein in the laboratory, and the receptor was found in vessel smooth muscle.
  • Cancer imaging research (J Neuroendocrinol, 2025): a DOTA-labelled kisspeptin-10 kept its activity at KISS1R and was cleared quickly from the blood of animals, as a first step towards a radioactive tracer for tumours that express the receptor.
  • Structure (Cell Rep, 2024; Sci Adv, 2024): cryo-EM structures with kisspeptin-10, kisspeptin-54 and TAK-448 are being used to design longer-lasting agonists.

Points to keep in mind

  • Small numbers: most experiments involved fewer than twenty people, often only four to seven per group.
  • Short exposure: most studies lasted hours or days, and none of those cited here went beyond twelve days.
  • Supervised settings: hormone levels were sampled frequently in clinical research facilities, which is very different from unsupervised use.
  • Hormone markers, not outcomes: the endpoints were blood hormone levels, not health benefits.
  • Material quality: studies used peptide of documented quality; products sold online may differ.

Overall

In research, kisspeptin-10 is a well-defined tool for stimulating GnRH release and exploring how the reproductive axis is timed and regulated. It has not been developed into an approved product, and the human data are limited to short, closely monitored studies.

References

  1. Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731-1737. PMID 8944003
  2. Lee DK, Nguyen T, O'Neill GP, et al. Discovery of a receptor related to the galanin receptors. FEBS Lett. 1999;446(1):103-107. PMID 10100623
  3. Ohtaki T, Shintani Y, Honda S, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001;411(6837):613-617. PMID 11385580
  4. Kotani M, Detheux M, Vandenbogaerde A, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. PMID 11457843
  5. Muir AI, Chamberlain L, Elshourbagy NA, et al. AXOR12, a novel human G protein-coupled receptor, activated by the peptide KiSS-1. J Biol Chem. 2001;276(31):28969-28975. PMID 11387329
  6. de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A. 2003;100(19):10972-10976. PMID 12944565
  7. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. PMID 14573733
  8. Messager S, Chatzidaki EE, Ma D, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci U S A. 2005;102(5):1761-1766. PMID 15665093
  9. Shahab M, Mastronardi C, Seminara SB, et al. Increased hypothalamic GPR54 signaling: a potential mechanism for initiation of puberty in primates. Proc Natl Acad Sci U S A. 2005;102(6):2129-2134. PMID 15684075
  10. Teles MG, Bianco SD, Brito VN, et al. A GPR54-activating mutation in a patient with central precocious puberty. N Engl J Med. 2008;358(7):709-715. PMID 18272894
  11. George JT, Veldhuis JD, Roseweir AK, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011;96(8):E1228-E1236. PMID 21632807
  12. Chan YM, Butler JP, Pinnell NE, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96(6):E908-E915. PMID 21470997
  13. Jayasena CN, Nijher GM, Comninos AN, et al. The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans. J Clin Endocrinol Metab. 2011;96(12):E1963-E1972. PMID 21976724
  14. Chan YM, Butler JP, Sidhoum VF, et al. Kisspeptin administration to women: a window into endogenous kisspeptin secretion and GnRH responsiveness across the menstrual cycle. J Clin Endocrinol Metab. 2012;97(8):E1458-E1467. PMID 22577171
  15. Topaloglu AK, Tello JA, Kotan LD, et al. Inactivating KISS1 mutation and hypogonadotropic hypogonadism. N Engl J Med. 2012;366(7):629-635. PMID 22335740
  16. Jayasena CN, Abbara A, Narayanaswamy S, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod. 2015;30(8):1934-1941. PMID 26089302
  17. d'Anglemont de Tassigny X, Jayasena CN, Murphy KG, et al. Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo. PLoS One. 2017;12(5):e0176821. PMID 28464043
  18. Chan YM, Lippincott MF, Sales Barroso P, et al. Using kisspeptin to predict pubertal outcomes for youth with pubertal delay. J Clin Endocrinol Metab. 2020;105(8):e2717-e2725. PMID 32232399
  19. Shen S, Wang D, Liu H, et al. Structural basis for hormone recognition and distinctive Gq protein coupling by the kisspeptin receptor. Cell Rep. 2024;43(7):114389. PMID 38935498
  20. Wu Z, Chen G, Qiu C, et al. Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptor. Sci Adv. 2024;10(33):eadn7771. PMID 39151001
  21. Kleynhans J, Reeve R, Driver CHS, et al. Synthesis and characterisation of DOTA-kisspeptin-10 as a potential gallium-68/lutetium-177 pan-tumour radiopharmaceutical. J Neuroendocrinol. 2025;37(3):e13487. PMID 39775975
  22. Pierret ACS, Patel AH, Daniels E, et al. Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders. Andrology. 2026;14(4):1002-1016. PMID 39834030